Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $11.6 million.

  • Aytu Biopharma's Operating Expenses fell 710.68% to $11.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.5 million, marking a year-over-year decrease of 26.24%. This contributed to the annual value of $53.7 million for FY2025, which is 594.93% up from last year.
  • As of Q4 2025, Aytu Biopharma's Operating Expenses stood at $11.6 million, which was down 710.68% from $10.7 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Operating Expenses peaked at $66.1 million during Q1 2022, and registered a low of $10.4 million during Q1 2025.
  • Moreover, its 5-year median value for Operating Expenses was $18.1 million (2023), whereas its average is $21.6 million.
  • In the last 5 years, Aytu Biopharma's Operating Expenses surged by 20855.23% in 2021 and then plummeted by 6777.8% in 2023.
  • Quarter analysis of 5 years shows Aytu Biopharma's Operating Expenses stood at $23.6 million in 2021, then grew by 2.41% to $24.2 million in 2022, then crashed by 52.58% to $11.5 million in 2023, then increased by 8.94% to $12.5 million in 2024, then dropped by 7.11% to $11.6 million in 2025.
  • Its Operating Expenses was $11.6 million in Q4 2025, compared to $10.7 million in Q3 2025 and $17.9 million in Q2 2025.